Navigation Links
ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) infection. ImQuest scientists will investigate the therapeutic potential and mechanism of action of ATI-0810 (Formerly PG301029) and a series of related chemical compounds. PG301029 is a highly novel transcriptional inhibitor of HCV replication, yielding a significant reduction of viral RNA synthesis in infected cells, and laboratory studies have demonstrated the compound to be less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology studies indicate that the compound is well tolerated and has a pharmacokinetic profile appropriate for drug development. The ImQuest research team will be led by Principal Investigator Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research. The funded studies will permit ImQuest to define other potent transcriptional inhibitors of HCV, investigate the mechanism of action of the active molecules and provide additional rationale for the development of a combination anti-HCV therapy using the lead molecules.

"We believe that the addition of a novel agent such as PG301029 to the current standard of care for HCV infected individuals will greatly enhance the percentage of patients that are able to achieve a robust and durable antiviral response to therapy," said Dr. Robert W. Buckheit, Jr., Executive Vice President of ImQuest. "Our data provide adequate rationale for the expedited development of PG301029 for HCV infection, and provide a platform to identify novel cellular and viral targets for future antiviral therapeutic development efforts."

The research continues the collaborative scientific partnership between ImQuest and Arisyn Therapeutics for the development of Arisyn Therapeutic's portfolio of antiviral and anticancer products.

ImQuest BioSciences Inc. is a privately held U.S. company located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

Arisyn Therapeutics Inc. is a privately held virtual biotechnology company headquartered in Frederick Maryland with a mission of identifying novel first in class inhibitors for infectious diseases and cancer based on their transcription targeted therapeutic agent platform.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.

SOURCE ImQuest BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
3. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
4. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
6. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
7. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
8. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
9. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
10. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
11. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
Post Your Comments:
(Date:11/30/2015)... Texas , Nov. 30, 2015  Hanger, Inc. ... amendment and restatement of the terms of its previously ... Solicitation") relating to its $200,000,000 aggregate principal amount 7⅛% ... other things, (i) the consent fees payable pursuant to ... on the Notes and (iii) the expiration date of ...
(Date:11/30/2015)... NAMUR , Belgium , Nov. 30, ... life sciences company focused on developing blood-based diagnostic tests for ... announced the Company will present at the LD Micro Conference, ... Los Angeles, CA. Attending from VolitionRx will ... and Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... RoamRight, a leading ... with Public Television’s Travel With Kids to promote family vacations around ... family as they explore international destinations and educate families about the people and places ...
(Date:11/30/2015)... ... November 30, 2015 , ... Advocare Orthopedic ... orthopedic care. Led by John Vitolo, M.D., the center offers their patients ... team at Advocare Orthopedic & Sports Medicine is ready to help their patients ...
(Date:11/30/2015)... ... November 30, 2015 , ... International telepathology consultations ... and KingMed Diagnostics researchers. Their review of more than 1,500 ... UPMC pathologists resulted in significantly altered treatment plans for more than half of ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for Clinical Pathology (ASCP) announced ... Day 2015. On Nov. 30, ASCP shared its “Give a minute. Get tested. Find ... and the importance of getting tested for HIV. , ASCP has asked members to ...
(Date:11/30/2015)... ... ... An inventor from Charlottesville, Va., is concerned about the need for peace and ... due to loud noises," she said, "so I decided that there needs to be ... radio waves and microwaves." , The baby BABY MUFF prevents loud noises, radio waves ...
Breaking Medicine News(10 mins):